scholarly journals Biomarkers and trial‐ready cohorts for Alzheimer’s disease clinical trials in the Down syndrome population

2020 ◽  
Vol 16 (S9) ◽  
Author(s):  
Juan Fortea
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Down Syndrome

scholarly journals Integrating Biomarker Outcomes into Clinical Trials for Alzheimer’s Disease in Down Syndrome

2020 ◽  
pp. 1-4 ◽  
Author(s):  
M.S. Rafii ◽  
S. Zaman ◽  
B.L. Handen
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trial ◽  
Clinical Trials ◽  
Down Syndrome ◽  
Natural History ◽  
New Information ◽  
History Of ◽  
Clinically Meaningful Outcomes

The NIH-funded Alzheimer’s Biomarker Consortium Down Syndrome (ABC-DS) and the European Horizon 21 Consortium are collecting critical new information on the natural history of Alzheimer’s Disease (AD) biomarkers in adults with Down syndrome (DS), a population genetically predisposed to developing AD. These studies are also providing key insights into which biomarkers best represent clinically meaningful outcomes that are most feasible in clinical trials. This paper considers how these data can be integrated in clinical trials for individuals with DS. The Alzheimer’s Clinical Trial Consortium - Down syndrome (ACTC-DS) is a platform that brings expert researchers from both networks together to conduct clinical trials for AD in DS across international sites while building on their expertise and experience.

Adults with Down syndrome in randomized clinical trials targeting prevention of Alzheimer's disease

2021 ◽  
Author(s):  
Wayne Silverman ◽  
Sharon J. Krinsky‐McHale ◽  
Warren B. Zigman ◽  
Nicole Schupf ◽  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Down Syndrome ◽  
Randomized Clinical Trials
Sign in / Sign up

Export Citation Format

Share Document